Black Diamond Therapeutics
Yahoo Finance • last year
With 58% ownership, Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) boasts of strong institutional backing
Key Insights Significantly high institutional ownership implies Black Diamond Therapeutics' stock price is sensitive to their trading actions 53% of the business is held by the top 6 shareholders Ownership research along with analyst for... Full story
Yahoo Finance • last year
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass. and NEW YORK, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients wi... Full story
Yahoo Finance • last year
Black Diamond Therapeutics Inc (BDTX) Reports Q3 2023 Financial Results and Corporate Update
Black Diamond Therapeutics Inc (NASDAQ:BDTX) reported Q3 2023 financial results, with a net loss of $23.0 million compared to $21.7 million in the same period in 2022. The company's cash, cash equivalents, and investments stood at $144.3 m... Full story
Yahoo Finance • last year
Black Diamond Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Presented BDTX-1535 Phase 1 dose escalation data showing durable anti-tumor activity and favorable safety profile in NSCLC patients across heterogeneous EGFR mutations at the October 2023 AACR-NCI-EORTC International Conference on Molecula... Full story
Yahoo Finance • last year
Black Diamond Therapeutics Presents Dose Escalation Data Demonstrating Durable Responses in Patients with NSCLC from Phase 1 Trial of BDTX-1535
Initial results from BDTX-1535 dose escalation show durable activity in patients with NSCLC across heterogeneous EGFR mutation subtypes No new safety or tolerability signal reported across all three active once daily doses of 100mg, 200... Full story
Yahoo Finance • last year
Black Diamond Therapeutics to Present Preclinical and Clinical Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
CAMBRIDGE, Mass. and NEW YORK, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision oncology company developing therapies that target families of oncogenic mutations in patients wi... Full story
Yahoo Finance • last year
Black Diamond Therapeutics Announces CEO Transition
Current Chairman of the Board and industry veteran Mark Velleca appointed CEO CAMBRIDGE, Mass. and NEW YORK, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision oncology company... Full story
Yahoo Finance • 2 years ago
Black Diamond Therapeutics Announces Pricing of Public Offering of Common Stock
CAMBRIDGE, Mass and NEW YORK, June 29, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision oncology company developing MasterKey therapies that target families of oncogenic mutations in pa... Full story
Yahoo Finance • 2 years ago
Black Diamond Therapeutics Announces Proposed Public Offering of Common Stock
CAMBRIDGE, Mass. and NEW YORK, June 28, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision oncology company developing MasterKey therapies that target families of oncogenic mutations in p... Full story
Yahoo Finance • 2 years ago
Black Diamond Therapeutics Announces Initial Dose Escalation Data Demonstrating Anti-Tumor Activity of BDTX-1535 in Non-Small Cell Lung Cancer Patients Across Multiple EGFR Mutation Families
BDTX-1535, an epidermal growth factor receptor (EGFR) MasterKey inhibitor, demonstrates clinical proof of activity for MasterKey mutation-targeting approach based on radiographic tumor responses and circulating tumor DNA changes in NSCLC p... Full story
Yahoo Finance • 2 years ago
Black Diamond Therapeutics Announces Promotion of Melanie Morrison to Chief Development Officer
CAMBRIDGE, Mass. and NEW YORK, June 13, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision oncology medicine company developing MasterKey therapies designed to overcome limitations of exi... Full story
Yahoo Finance • 2 years ago
Black Diamond Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
On track to provide clinical update from dose-escalation portion of Phase 1 clinical trial of EGFR MasterKey inhibitor BDTX-1535 in the second half of 2023; Dose Expansion cohorts expected to open in 2023FDA clearance of IND application fo... Full story
Yahoo Finance • 2 years ago
Black Diamond Therapeutics to Present at the Stifel 2023 Targeted Oncology Days
CAMBRIDGE, Mass. and NEW YORK, April 18, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision oncology medicine company developing MasterKey therapies designed to overcome limitations of ex... Full story
Yahoo Finance • 2 years ago
Black Diamond Therapeutics Presents Trial in Progress Poster for BDTX-1535 and Preclinical Data on BDTX-1535 and BDTX-4933 at the 2023 American Association of Cancer Research Annual Meeting
BDTX-1535 Phase 1 dose escalation ongoing in NSCLC harboring sensitizing EGFR mutations with or without CNS disease and recurrent GBM expressing EGFR alterations; Dose expansion cohorts expected to open in 2023 In preclinical tumor models,... Full story
Yahoo Finance • 2 years ago
Black Diamond Therapeutics to Present at the Cowen 43rd Annual Health Care Conference
CAMBRIDGE, Mass. and NEW YORK, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision oncology medicine company developing novel MasterKey therapies targeting families of oncogenic dri... Full story
Yahoo Finance • 2 years ago
Black Diamond Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass. and NEW YORK, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision oncology medicine company developing MasterKey therapies designed to overcome limitations of exi... Full story
Yahoo Finance • 2 years ago
Black Diamond Therapeutics Announces Changes to Board of Directors
CAMBRIDGE, Mass. and NEW YORK, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today announced that... Full story
Yahoo Finance • 2 years ago
Black Diamond Therapeutics Announces Spinout of Launchpad Therapeutics, Inc., an Antibody-Focused Precision Oncology Company
- $30M Series A investment from Versant Ventures and NEA- CAMBRIDGE, Mass. and NEW YORK, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery a... Full story
Yahoo Finance • 2 years ago
Black Diamond Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Presented new data at the 34th EORTC-NCI-AACR Symposium highlighting robust preclinical anti-tumor activity of BDTX-1535 and BDTX-4933 across multiple families of oncogenic mutations while sparing wild type; both MasterKey therapies demons... Full story
Yahoo Finance • 2 years ago
Black Diamond Therapeutics Presents Preclinical Data on BDTX-1535 and BDTX-4933 at the 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
BDTX-1535 is an irreversible MasterKey inhibitor of multiple EGFR alterations that utilize similar activated oncogenic EGFR conformations to drive tumor cell growth in GBM and NSCLC BDTX-1535 demonstrated potent systemic and CNS anti-tumor... Full story
